Croda International (CRDA) Q3 2025 TU earnings summary

Executive summary

• Group sales increased 6.5% in constant currency, reaching £424.7m in Q3 2025, marking the sixth consecutive quarter of growth, led by Beauty Actives, Fragrances & Flavours, and Crop Protection despite a challenging market environment.

• Innovation-led growth is driving sales, particularly in actives and F&F, with broad-based customer demand and ongoing recovery in Crop.

• Transformation plan execution remains on track, focusing on portfolio optimization, local customer engagement, and cost-saving initiatives to support margin recovery.

Financial highlights

• Q3 2025 sales increased to £424.7m from £406.6m in Q3 2024, with low double-digit sales volume increases year-over-year, though product and business mix remained negative.

• Consumer Care sales up 6% reported and 8% constant currency; Life Sciences up 4% reported and 6% constant currency.

• Industrial Specialties sales fell 1% reported but rose 1% at constant currency.

• Like-for-like prices were largely consistent with the prior year.

• Forex headwinds expected to impact full-year profit by approximately £10 million, with strengthening Sterling and transactional exposures adversely impacting profit.

• Full-year group adjusted profit before tax expected in the range of £265–£295 million at constant currency.

Outlook and guidance

• Full-year guidance remains unchanged despite market uncertainty, currency headwinds, and lower order visibility.

• Q4 is expected to be seasonally lower in absolute sales due to typical year-end customer working capital management.

• Pricing trends are expected to remain flat year-on-year, with positive price/mix expected to return as volumes normalize by 2026.

• Volume growth is anticipated to continue into 2026, with operational leverage and margin accretion as utilization rates return to historic levels.

• Challenging trading environment and low order book visibility anticipated to persist.